CA2187336A1 - Formulations pharmaceutiques utilisees dans le traitement de la pollinose du cedre du japon - Google Patents

Formulations pharmaceutiques utilisees dans le traitement de la pollinose du cedre du japon

Info

Publication number
CA2187336A1
CA2187336A1 CA002187336A CA2187336A CA2187336A1 CA 2187336 A1 CA2187336 A1 CA 2187336A1 CA 002187336 A CA002187336 A CA 002187336A CA 2187336 A CA2187336 A CA 2187336A CA 2187336 A1 CA2187336 A1 CA 2187336A1
Authority
CA
Canada
Prior art keywords
seq
cji
peptide
peptides
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002187336A
Other languages
English (en)
Inventor
Henry M. Franzen
Stephen Palmer Powers
Mei-Chang Kuo
Sean Evans
Ze'ev Shaked
Xian Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Immulogic Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharmaceutical Corp filed Critical Immulogic Pharmaceutical Corp
Publication of CA2187336A1 publication Critical patent/CA2187336A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention se rapporte à de nouveaux peptides de Cry j I qui ont été modifiés dans le cadre d'un système de préformulation afin de développer un médicament optimisé destiné au traitement des personnes souffrant d'allergie due à l'allergène du pollen du cèdre du Japon ou à un allergène qui présente une réaction croisée immunologique avec l'allergène du cèdre du Japon. Ces peptides modifiés possèdent certaines caractéristiques uniques qui les rendent particulièrement aptes à être utilisées dans la formulation de médicaments. La présente invention se rapporte également à des compositions thérapeutiques et à des formulations multipeptidiques qui ont été optimisées pour adapter et conserver des caractéristiques uniques des peptides modifiés Cry j I, et en même temps, afin d'obtenir un effet thérapeutique maximum lorsqu'ils sont utilisés dans des régimes thérapeutiques s'appliquant au traitement de la pollinose du cèdre du Japon chez l'homme.
CA002187336A 1994-04-08 1995-04-06 Formulations pharmaceutiques utilisees dans le traitement de la pollinose du cedre du japon Abandoned CA2187336A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22624894A 1994-04-08 1994-04-08
US35022594A 1994-12-06 1994-12-06
US08/350,225 1994-12-06
US08/226,248 1994-12-06

Publications (1)

Publication Number Publication Date
CA2187336A1 true CA2187336A1 (fr) 1995-10-19

Family

ID=26920341

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002187336A Abandoned CA2187336A1 (fr) 1994-04-08 1995-04-06 Formulations pharmaceutiques utilisees dans le traitement de la pollinose du cedre du japon

Country Status (5)

Country Link
EP (1) EP0756629A1 (fr)
JP (1) JP4179422B2 (fr)
AU (1) AU2241995A (fr)
CA (1) CA2187336A1 (fr)
WO (1) WO1995027786A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773003A (en) * 1995-03-31 1998-06-30 Immulogic, Inc. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
DE69637089T2 (de) * 1995-03-31 2008-01-17 Xenova Research Ltd., Slough Hapten-Träger-Konjugate zur Anwendung in der Drogen-Missbrauchs-Therapie
JP3734040B2 (ja) * 1996-06-14 2006-01-11 明治乳業株式会社 T細胞エピトープペプチド
JP4176750B2 (ja) * 1996-06-14 2008-11-05 明治乳業株式会社 T細胞エピトープペプチド
SE9603468D0 (sv) * 1996-09-23 1996-09-23 Astra Ab New compounds
SE9603463D0 (sv) * 1996-09-23 1996-09-23 Astra Ab New compounds
US7025964B1 (en) * 1996-11-13 2006-04-11 Meiji Dairies Corporation Peptide-based immunotherapeutic agent
JP3939401B2 (ja) * 1997-09-17 2007-07-04 三共株式会社 ペプチド及びその用途
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
WO2005027774A2 (fr) * 2003-09-17 2005-03-31 Baby Boost, Inc. Procede et appareil de prevention d'allergies
JP3987562B2 (ja) * 2006-10-23 2007-10-10 第一三共株式会社 ペプチド及びその用途
JP3987563B2 (ja) * 2006-10-23 2007-10-10 第一三共株式会社 ペプチド及びその用途
JP2012240978A (ja) * 2011-05-20 2012-12-10 Nitto Denko Corp 医薬組成物及びゼリー状製剤
US20120294894A1 (en) * 2011-05-20 2012-11-22 Nitto Denko Corporation Pharmaceutical composition and method for producing the same
JP2012240975A (ja) * 2011-05-20 2012-12-10 Nitto Denko Corp 医薬組成物及びゼリー状製剤
JP6200630B2 (ja) * 2012-02-10 2017-09-20 オーストリッチファーマ株式会社 医薬組成物
WO2016209959A2 (fr) 2015-06-22 2016-12-29 Alk-Abelló A/S Combinaisons de peptides et leur utilisation dans le traitement de l'allergie aux pollen de cèdre

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001560A1 (fr) * 1991-07-12 1994-01-20 Immulogic Pharmaceutical Corporation Proteines et peptides allergenes tires du pollen du cedre du japon

Also Published As

Publication number Publication date
AU2241995A (en) 1995-10-30
JP4179422B2 (ja) 2008-11-12
EP0756629A1 (fr) 1997-02-05
WO1995027786A1 (fr) 1995-10-19
JPH09511747A (ja) 1997-11-25

Similar Documents

Publication Publication Date Title
CA2187336A1 (fr) Formulations pharmaceutiques utilisees dans le traitement de la pollinose du cedre du japon
AU724333B2 (en) Immunomodulatory peptides of vespid antigen 5
NZ502480A (en) Pharmaceutical peptide formulations for treatment of dust mite allergy
JP2002504491A (ja) インスリンのペプチドアナログを使用した糖尿病の処置のための方法
JPH10509428A (ja) 活性依存性神経栄養因子の神経栄養ペプチド
WO1993015750A1 (fr) Utilisation de peptides synthetiques pour l'induction de tolerance a des epitopes de cellules t et b d'autoantigenes
US7914778B2 (en) Methods of treatment using IL-16 antagonist peptides
CA2203018A1 (fr) Peptides a specificite pour des anticorps contre une proteine basale de myeline et administration de peptides de proteines basales de myeline a des patients atteints de sclerose en plaque
EP0770681A2 (fr) Epitopes de lymphocytes T des principaux allergènes d'Ambrosia artemisiifolia
EP0755407B1 (fr) Formulations pharmaceutiques a base de peptides utiles pour traiter l'allergie aux acariens detriticoles
JPH09504167A (ja) ドクムギ花粉アレルゲンのt細胞エピトープ
US20030152581A1 (en) Compound and method for the prevention and/or the treatment of allergy
IL105822A (en) Pharmacy products for use in the treatment of tropical spasticity
KR100540417B1 (ko) 펩티드 면역 요법 치료제
US20030022826A1 (en) Use of synthetic peptides to induce tolerance to pathogenic T and B cell epitopes of autoantigens or infectious agents
US6335020B1 (en) Allergenic peptides from ragweed pollen
JPH08502163A (ja) 杉花粉由来のアレルゲン性蛋白質及びペプチド
JPH07505878A (ja) Hivエンベロープ糖タンパク質から誘導された合成ポリペプチド
JP2001518451A (ja) アレルゲンの非アナフィラキシー形およびその使用
US7112333B1 (en) T cell epitopes of ryegrass pollen allergen
JPH10506877A (ja) ライグラス花粉アレルゲンのt細胞エピトープ
US5686417A (en) Peptide T and related peptides in the treatment of HTLV-1 myelopathy and multiple sclerosis
KR100562821B1 (ko) T세포에피토프펩티드

Legal Events

Date Code Title Description
FZDE Discontinued